introduction
Colorectal cancer corresponds to the third more incident (9.7%) and the fourth deadlier (8.5%) cancer of all cancers in the world. 1 In Brazil, it is the third more incident cancer. 2 Clinical T3/T4 or node-positive rectal cancer (locally advanced rectal cancer) patients are usually assigned to preoperative or postoperative chemoradiotherapy.
Previous published studies have shown that preoperative chemoradiotherapy significantly improves disease-free survival and local control compared with postoperative chemoradiotherapy. 3, 4 In spite of different neoadjuvant chemoradiation therapy regimens available for treatment of rectal cancer (RC), down staging can be observed only in 20% of patients, 5 and response to therapy is usually done with the analysis of the surgical specimens, known as the gold standard. Tumor regression grade is mostly associated with prognosis and is of great interest due to survival. 5 Complete and partial regression have improved long-term outcome in patients with rectal carcinoma after preoperative chemoradiation. [3] [4] [5] [6] The ability to predict responders to preoperative chemoradiation in RC using conventional imaging methods (CT, US, MRI) alone or in combination is a difficult task, with non-reliable data. 7, 8 Accurate restaging before operation is important to determine the best surgical strategy. Surgical extension and aggressiveness, and sphincter preservation should be considered in light of the response to neoadjuvant treatment, ideally through a noninvasive test. 9 Fluorine-18-labeled fluorodeoxyglucose-positron emission tomography studies ( 18 F-FDG) have been used to evaluate response to therapy in different cancer types. [10] [11] [12] [13] In rectal cancer, previously published data have shown promising use of 18 F-FDG PET/CT as an important tool to discriminate responders from non-responders. 7-9,14-19 18 F-FDG PET/CT is a test capable of providing metabolic information of viable cancer cells based on radiotracer retention in the compartment of interest, mediated by an enzyme-substrate reaction. However, there is no consensus on how the quantitative analysis should be used to predict response to therapy using 18 F-FDG PET/CT. 18 F-FDG-PET images have some limitations regarding the provision of accurate information on external and internal contours of the tumor because of the limited spatial resolution associated with this imaging modality. Despite the extensive use of the most intense 18 F-FDG tumor uptake value (known as SUV max ) to represent tumor glycolytic consumption using PET images, there is a trend to apply metabolic volume instead.
Due to the inherited heterogeneous behavior of cancer cells, expressing the glucose metabolism of the entire tumor in a single voxel might not be the best manner. Tumor metabolism using volume based on PET images seems a more precise representation than SUV max . Thus, several approaches have been used for tumor segmentation with 18 F-FDG-PET images [20] [21] [22] [23] [24] [25] [26] for the evaluation of the metabolic pattern of the entire tumor. However, these results are still undergoing evaluation due to large variability depending on the choice of the threshold employed, and none of them were used as a non-subjective way to generate PET tumor volumes. [20] [21] [22] [23] [24] [25] [26] Thus, the aim of our study was to evaluate a noninvasive and non-subjective method for tumor segmentation using 18 F-FDG PET/CT imaging to predict response to therapy in patients with rectal cancer that underwent neoadjuvant chemoradiation therapy. To date and to our knowledge, this is the first study to use this methodology to evaluate response to therapy in rectal cancer patients.
Method
The study retrospectively evaluated 17 patients with histopathological confirmation of adenocarcinoma of rectum whom underwent 18 F-FDG PET/CT before and eight weeks after neoadjuvant chemoradiation at our institution. Staging was done according to the TNM system 27 presented in the 7 th edition of the American Joint Committee on Cancer (AJCC) and included colonoscopy, high-resolution magnetic resonance imaging (MRI) and abdominal and chest computerized tomography (CT) scans. Patients with baseline metastatic disease were excluded. All patients underwent standard neoadjuvant long-course chemoradiation as previously described. 4 Briefly, the regimen consisted of 50.4 Gy delivered on weekdays to the pelvis and a 9 Gy boost to the primary tumor. Concomitantly, chemotherapy (5-fluorouracil and leucovorin) was delivered on the 1 st and 5 th week of radiation therapy. Surgical resection of the rectum was performed after the second PET scan for all patients. The study was approved by the human research ethics committee, and all of the study's participants signed an informed consent form aware that their privacy rights would be observed. 18 F-FDG PET/CT scans were performed according to our research protocol for oncological patients using a Discovery 690 PET/CT scanner (GE, Milwaukee, WI, USA). Patients fasted for at least six hours before the intravenous administration of 3.7 MBq/kg (mean 251.6 ± 62.9 MBq and 244.2 ± 66.6 MBq, before and after therapy, respectively) body weight of 18 F-FDG. Blood glucose levels was checked before tracer administration (mean 95.2 ± 9.1 mg/dL and 95.8 ± 9.3 mg/dL, before and after therapy, respectively) and patients with glucose levels higher than 190 mg/dL were excluded from the study. CT scans were performed from the top of the head to mid thigh approximately 60 minutes (mean 95.8 ± 9.3 minutes and 91.1 ± 11.4 minutes, before and after therapy, respectively) after intravenous injection of 18 F-FDG using a lowdose protocol (120 kV, smart mA) for attenuation map without diagnostic purpose and without oral or intravenous contrast media. Then, PET images were acquired with 2 minutes per bed position for the same region. All PET images were reconstructed using OSEM-like reconstruction algorithm with 2 interations and 24 subsets.
The 18 F-FDG PET/CT images were evaluated independently by two board certified nuclear physicians blinded to all imaging studies and clinical and pathological results. In case of discrepancy, the interpretation was made by consensus between the investigators. All lesions were analyzed semiquantitatively based on the maximum standardized uptake value (SUV max ) in the transaxial plane method normalized by lean body mass and were considered pre-and post-therapy (SUV max1 and SUV max2 , respectively).
In order to evaluate volumetric tumor glucose consumption, an algorithm for tumor segmentation using PET images was applied, which was initially validated in esophageal cancer patients. 28, 29 This methodology uses the 18 F-FDG uptake in the liver as a control to individualize threshold for tumor segmentation. Briefly, a regionof-interest comprising the entire organ on a transaxial slice was drawn in the liver and mean and standard deviation of the uptake value of 18 F-FDG (L mean and L SD , respectively) were calculated. Meanwhile, the highest tumor uptake value in a voxel (T max ) was also calculated. Then, to individualize the threshold for tumor segmentation, a lower SUV value (T 2SD ) was generated as a result of the following formula: T 2SD = T max -(L mean + 2xL SD ). Using a region-growing methodology, volumes of interest from a seed point (voxel with highest uptake of 18 F-FDG in the tumor: T max ) with an specific threshold (T 2SD ) recognizes all surrounding areas to capture up voxels with the difference of initial value based on the segmentation algorithm. For that, a dedicated workstation was used (Advantage Windows Workstation, GE, Milwaukee, WI, USA).
After generating the target lesion volume (Vol 2SD ), the program calculates the average SUV volume (SUV 2SD ), and the product of Vol 2SD with SUV 2SD determines the total lesion glycolysis (TLG 2SD ). Fixed thresholds (40%, 50% and 60%) were also applied to generate PET-volumes (Vol 40% , Vol 50% and Vol 60% , respectively), averaged SUVs (SUV 40% , SUV 50% and SUV 60% , respectively) and the total lesion glycolysis (TLG 40% , TLG 50% , and TLG 60% , respectively). All variables were calculated for each patient before and after neoadjuvant therapy. In addition, percentage of differences between pre-and post-therapy analyses was also calculated for each parameter as follows: %∆SUV=[(SUV 1 -SUV 2 )/SUV 1 ]x100, %∆Vol=[(Vol 1 -Vol 2 )/Vol 1 ]x100% and %∆TLG=[(TLG 1 -TLG 2 )/TLG 1 ] x100.
Response was assessed using the protocol recommendations by Dworak et al. 30 Resected specimens were analyzed by the same pathologist with particular expertise in gastrointestinal diseases. Tumor response to neoadjuvant therapy was scored using the semiquantitative evaluation of histological regression according to the tumor regression grade (TRG) scale: 30 Table 1 shows various quantitative metabolic measurements using 18 F-FDG PET/CT images pre-and post-neoadjuvant therapy using different methodologies. All variables revealed significant reduction after chemoradiation therapy (p<0.01 for all). Table 2 shows the percentage changes among the variables evaluated in the present study.
Among all variables calculated using 18 F-FDG PET/CT images (Table 1) , there were significant differences between responders (Dworak 3 or 4) vs. non-responders (Dworak 0-2) for SUV max-2 (5.8 ± 2.4 vs. 10.5 ± 3.0, p<0.01), SUV 2SD-2 (3.3 ± 0.4 vs. 4.5 ± 1.2, p<0.05), SUV 40%-2 (3.5 ± 0.9 vs. 6.2 ± 1.9, p<0.05), SUV 50%-2 (4.1 ± 1.0 vs. 7.1 ± 2.1, p<0.05) and SUV 60%-2 (4.7 ± 1.1 vs. 8.1 ± 2.4, p<0.05). However, there was no significant difference between responders and non-responders for all of percentage change variables presented in Table 2 .
In order to determine the best cutoff values to differentiate responders from non-responders, ROC analyses were performed for all variables. Table 3 summarizes the variables with significant areas under the curve (p<0.05, except for the SUV 2SD-1 ). However, the variable SUV 2SD-1 did not reach statistical significance (p=0.055) with the studied sample, the proposed methodology (SUV 2SD-2 ) was able to segmentation generated using 2SD individualized algorithm. C. Tumor segmentation generated using 40% threshold. D. Tumor segmentation generated using 50% threshold. E. Tumor segmentation generated using 60% threshold.
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differentiate responders from non-responders with 60% and 82% of sensitivity and specificity, respectively. The proposed methodology showed lower sensitivity but higher specificity to discriminate responders from non-responders compared to fixed thresholds (Table 3 ). Figure 2 shows the significant ROC analyses for the thresholds applied. Figure 3 shows a typical example of 18 F-FDG PET/CT imaging tumor segmentation using 2SD individualized algorithm.
discussion
There is an undeniable interest in assessing response to neoadjuvant chemoradiation in rectal cancer noninvasively with 18 F-FDG PET/CT. Tumor metabolic changes using volumetric analyses with PET images seem to be a more precise representation than SUV max . However, there is no consensus about the threshold used for tumor segmentation in this matter. As far as we know, our study is the first in which the proposed methodology of using individualized threshold to segment tumor using 18 F-FDG PET/CT images in rectal cancer patients is addressed. This methodology has been applied in esophageal cancer patients 29 with promising results to predict response to neoadjuvant therapy and patient outcome. By using this methodology, SUV 2SD-1 enabled the discrimination of responders from non-responders with reasonable sensitivity and specificity (83.3% and 72.7%, respectively), while the SUV 2SD-2 showed approximate values (60.0% and 81.8%, respectively). SUV 2SD-1 takes into account tumor heterogeneity and, therefore, could be used to predict patients with better outcome before the beginning of neoadjuvant therapy.
Accurate therapeutic response evaluation is crucial because it can guide optimization of the surgical approach (i.e. sphincter-sparing surgery in low rectal tumors), or less aggressive treatment in minimally-advanced tumors. Conventional imaging modalities cannot differentiate fibrosis from viable tumor cells in residual masses after neoadjuvant chemoradiation therapy, therefore being of limited impact on the prediction of pathological response. 7, 8 On the other hand, 18 F-FDG PET/CT has been proven to be able to predict therapeutical response accurately.
Tumor response varies considerably and, in addition, not all patients benefit equally from treatment. Thus, assessment of potential predictors of histological response using 18 F-FDG PET/CT in patients undergoing preoperative treatment could help develop tailored therapy strategies. Our study showed that among the 35.3% of responders (Dworak 3 and 4) , some analyzed variables were able to discriminate them from non-responders (SUV max-2 , SUV 2SD-2 , SUV 40%-2 , SUV 50%-2 and SUV 60%-2 ) and the effectiveness of neoadjuvant therapy was in accordance with a previous study. 31 Guerra et al. 32 showed that SUV max after therapy was the best predictor of pathologic complete response (pCR). The values found were 3.6 ± 1.4 for responders and 6.6 ± 2.1 (p=0.0009) for non-responders. 32 Our study showed similar results for SUV max-2 with slightly higher values (5.3 ± 2.2 and 10.4 ± 2.9, respectively) compared to the findings of Guerra et al. 32 These differences could be related to the methodologies applied: 1. SUV correction for the patients' body weight rather than lean body mass, and 2. scan time after chemoradiation, twelve weeks instead of eight weeks applied in our study, respectively.
A study by Kim et al. 33 conducted univariate and multivariate analyses and found post-chemoradiation SUV max as an independent predictor of complete pathological response (pCR). The predictive values of SUV max post-chemoradiation proved to be a value for pCR with a sensitivity of 73.7%, specificity of 63.7% and accuracy of 64.9% for a cutoff value of 3.55. In our study, the cutoff value for SUV max-2 of 7.9 showed sensitivity of 83.3% and specificity of 72.7% to discriminate responders (Dworak 3 and 4) from nonresponders (Dworak 0-2), a slightly different approach due to the same sample evaluated. Thus, both studies found that the predictive values of post-chemoradiation SUV max-2 present low sensitivity and specificity to motivate a change in the treatment plan for locally advanced rectal cancer.
In the meta-analysis with the largest number of patients (n=1,527), Li et al. 34 found SUV max2 and ∆%TRP to determine pCR alone. The results of subgroup analysis showed that ∆%SUV max before and after therapy had higher specificity to predict the degree of tumor regression than pCR alone. Unfortunately, ∆%SUV max in our study was not strong enough to separate responders from nonresponders due probably to the small sample size, which constitutes a limitation. The other potential issue related to the weakness of this variable might be related to inflammation after radiotherapy. Inflammatory cells can take 18 F-FDG up, mimicking viable cancer cells and limiting the use of this methodology for response evaluation.
The other variables SUV 40%-2 , SUV 50%-2 and SUV 60%-2 should be used with caution, since tumor segmentation using PET images with these thresholds has significant interference depending on the heterogeneity of the tumor. Thus, underestimation could be the main issue of this methodology to evaluate tumor response with unreliable results.
conclusion
Our study confirmed the predictive power of the variables using a noninvasive individualized methodology for tumor segmentation based on 18 F-FDG PET/CT imaging for response evaluation in patients with rectal cancer after neoadjuvant chemoradiation therapy. The reliability of these results should be applied to a larger number of patients and cannot exempt responders from radical surgery. It is also worth noting that there is a need to standardize the methodology of the tests using 18 F-FDG PET/ CT imaging so that the results can be compared. Although additional work remains to be done, the methodology presented in our study is of general interest, as it introduces a new perspective for the use of this imaging modality on the evaluation of chemoradiation therapy response, with potential clinical impact due to the personalized-type analysis for therapeutic response evaluation in rectal cancer patients.
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resuMo
Individualização na segmentação tumoral de imagens de 18 F-FDG PET/CT: a chave para avaliação de resposta terapêutica neoadjuvante em pacientes com câncer retal? Introdução: O câncer retal (RC) é uma doença de importância global, e o tratamento padrão para o câncer retal localmente avançado compreende quimiorradiação neoadjuvante seguida de cirurgia radical. Independentemente do uso extensivo da captação tumoral mais intensa do 18 F-FDG (conhecida como SUV max ) como representativo do consumo glicolítico do tumor nas imagens de PET, há uma tendência para aplicar volume metabólico. Dessa forma, o objetivo do presente estudo foi avaliar um mé-todo não invasivo de segmentação tumoral utilizando a 18 F-FDG PET para predizer a resposta à quimiorradioterapia neoadjuvante em pacientes com câncer de reto. Método: A amostra consistiu em pacientes com câncer retal em estádios II e III submetidos ao exame de 18 F-FDG PET/CT antes e oito semanas após a terapia neoadjuvante. Foi aplicada uma metodologia de segmentação tumoral individualizada para gerar volumes tumorais (SUV 2SD ). A resposta terapêutica foi avaliada nos espécimes ressecados utilizando as recomendações do protocolo de Dworak. Várias variáveis foram geradas e comparadas com os resultados histopatológicos. Resultados: Dezessete (17) pacientes foram incluídos e analisados. Foram observadas diferenças significativas entre os respondedores (Dworak 3 e 4) e não respondedores para SUV max-2 (p<0,01), SUV 2SD-2 (p<0,05), SUV 40%-2 (p<0,05), SUV 50%-2 (p<0,05) e SUV 60%-2 (p< 0,05). As análises ROC mostraram áreas significativas sob a curva (p<0,01) para a metodologia proposta, com sensibilidade e especificidade variando de 60% a 83% e 73% a 82%, respectivamente. Conclusão: O presente estudo confirmou o poder preditivo das variáveis utilizando uma metodologia não invasiva individualizada para segmentação tumoral baseada em imagens 18 F-FDG PET/CT para avaliação da resposta em pacientes com câncer retal após tratamento com quimiorradiação neoadjuvante. 
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